cdmo.directory
← Compare landing

Macrocyclics, Inc. vs 重庆兴泰濠制药有限公司 (Sintaho)

Auto-generated comparison by BioBM Editorial AI. This page highlights available profile evidence side by side and avoids drawing conclusions from missing fields.

Markdown mirror: /api/markdown/compare/macrocyclics/sintaho

CategoryMacrocyclics, Inc.重庆兴泰濠制药有限公司 (Sintaho)
Listed sitecdmocdmo
SummaryChelator-focused CDMO for radiopharmaceuticals, offering cGMP clinical-trial manufacture, custom synthesis scaled to kilogram quantities, bioconjugation, and HPLC/Q-TOF analytical testing.China-based API and CDMO/CMO supplier focused on cytotoxic and OEB5 high-potency APIs, peptides, and XDC compounds. Reports FDA on-site inspections in 2024 and 2025 and product registrations in more than 30 countries.
Services
  • API Synthesis & Manufacturing
  • Small Molecule Development & Manufacturing
  • Bioconjugation Services
  • Analytical Method Development & Validation
  • Peptide Manufacturing
  • API Synthesis & Manufacturing
  • HPAPI Manufacturing (High-Potency)
  • Peptide Manufacturing
  • Small Molecule Development & Manufacturing
Modalities
  • Radiopharmaceutical
  • Small Molecule
  • Peptide
  • Small Molecule
  • Peptide
Indications
  • Oncology
Data not yet provided.
LocationsData not yet provided.
  • Headquarters, Chongqing, Chongqing, China
CertificationsData not yet provided.
  • Internet Drug Information Service Qualification (Chongqing) · Identifier: （渝）-非经营性-2022-0020
ReviewsReview summary appears after site-level review signal gate opens.Review summary appears after site-level review signal gate opens.